Nuvalent, Inc.
General ticker "NUVL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.1B (TTM average)
Nuvalent, Inc. follows the US Stock Market performance with the rate: 54.3%.
Estimated limits based on current volatility of 1.9%: low 103.19$, high 107.10$
Factors to consider:
- Total employees count: 142 (+54.3%) as of 2024
- Top business risk factors: Transition to commercialization, Unproven drug discovery approach, Product liability, Labor/talent shortage/retention, Climate change and natural disasters
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [43.24$, 99.85$]
- 2025-12-31 to 2026-12-31 estimated range: [30.08$, 72.70$]
Financial Metrics affecting the NUVL estimates:
- Negative: with PPE of -21.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.40 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 93.70 > 63.39
- Negative: negative Net income
- Positive: -14.38 < Investing cash flow per share per price, % of -10.54
Short-term NUVL quotes
Long-term NUVL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $86.11MM | $149.49MM | $280.37MM |
| Operating Income | $-86.11MM | $-149.49MM | $-280.37MM |
| Non-Operating Income | $4.25MM | $23.27MM | $20.38MM |
| R&D Expense | $63.73MM | $113.24MM | $217.77MM |
| Income(Loss) | $-81.85MM | $-126.22MM | $-259.99MM |
| Taxes | $0.00MM | $0.00MM | $0.76MM |
| Profit(Loss)* | $-81.85MM | $-126.22MM | $-260.76MM |
| Stockholders Equity | $462.98MM | $700.56MM | $1,069.79MM |
| Assets | $482.46MM | $732.38MM | $1,141.75MM |
| Operating Cash Flow | $-64.97MM | $-99.74MM | $-185.06MM |
| Investing Cash Flow | $-10.66MM | $-143.53MM | $-573.51MM |
| Financing Cash Flow | $248.92MM | $336.85MM | $568.88MM |
| Earnings Per Share** | $-1.65 | $-2.17 | $-3.93 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.